Revenue segments as reported by the company.

Diabetes

Oncology

Immunology

Neuroscience

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Marketing, selling and administrative

Acquired in-process research and development

Asset impairment, restructuring and other special charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Eli Lilly

Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.

Cialis

Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.

Cymbalta

Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.

Gemzar

Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.

Methadone

Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.

Prozac

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Eli Lilly reports robust Q4 earnings, eyes growth in innovative therapies

Eli Lilly's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements, and strategic initiatives for future growth.
The company's focus on innovation, FDA approvals, and market expansion underscores its commitment to addressing unmet medical needs and driving shareholder value.
Challenges in physician education, obesity treatment development, and market access present areas for strategic focus and investment for sustained growth.
Opportunities in expanding manufacturing capacity, engaging with payers, and capitalizing on consumer interest in obesity treatments position Lilly for continued success in 2023.

Eli Lilly reports robust Q1 growth amidst capacity challenges

Eli Lilly's Q1 2023 performance reflects strong revenue growth and strategic investments in new products and facilities.
While facing challenges in capacity and supply pressure, the company's focus on pipeline advancements and market opportunities positions it for future growth.
Opportunities in international markets, cardiovascular trials, and product promotion present avenues for continued expansion and revenue growth.
Overall, Eli Lilly's financial performance, product strengths, and strategic initiatives demonstrate a resilient and growth-focused approach.

Eli Lilly reports robust Q2 earnings, eyes growth through innovation

Eli Lilly's Q2 earnings call showcased strong financial performance, revenue growth, and advancements in its pipeline, driven by key products and strategic investments.
The company faces challenges in managing increased expenses, supply chain constraints, and regulatory considerations, requiring strategic decision-making and operational agility.
Opportunities lie in expanding market access, leveraging innovative treatments like tirzepatide, and enhancing manufacturing capabilities to drive future growth and competitive advantage.
Overall, Lilly's focus on innovation, market expansion, and addressing health needs positions it well for sustained growth and leadership in the pharmaceutical industry.

Eli Lilly posts robust Q3 results, eyes expansion and commercial growth

Eli Lilly (LLY) showcased strong financial performance and pipeline advancements in Q3 2023.
Challenges include supply restrictions and pricing decisions, but opportunities lie in expansion plans and commercial coverage ramp-up.
Investors advised to focus on guidance range for insights into 2024 expectations.

Eli Lilly posts robust Q4 results, eyes global expansion opportunities

Eli Lilly's strong financial performance in Q4 2023, driven by revenue growth and operational efficiency, sets a solid foundation for future growth.
The company's strategic acquisitions, global expansion plans, and focus on innovation position it well for continued success and market leadership.
Challenges in drug development and manufacturing require careful navigation, but opportunities in new drug trials and market expansion offer avenues for growth.
Overall, Eli Lilly's 2023 was marked by productivity and anticipation of sustained momentum in 2024, reflecting a positive outlook for the company.

Eli Lilly reports robust Q1 growth, eyes pipeline opportunities

Eli Lilly's Q1 performance showcased strong revenue growth, driven by new products and global market expansion.
While facing challenges like low Zepbound volume and manufacturing complexities, Lilly's strengths in innovation and market presence position it well for growth.
Opportunities in pipeline advancements, differentiation in drug portfolios, and potential Alzheimer's treatments signal a promising future for the company.
Overall, Eli Lilly's strategic focus on growth, innovation, and market expansion sets a positive trajectory for continued success.

Eli Lilly reports stellar Q3 results, eyes global expansion opportunities

Eli Lilly's Q3 performance reflects robust revenue growth, driven by new products and strategic investments, positioning the company for continued success.
Key pipeline advancements and revenue guidance raise optimism for future growth, with a focus on global scaling and market expansion initiatives.
Challenges in patient adherence and treatment efficacy are being addressed, while opportunities in market penetration and revenue growth are actively pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

INDIANAPOLIS, Feb. 17, 2021 /PRNewswire/ -- Tirzepatide led to significant A1C and body weight reductions from baseline in adults with type 2 diabetes in Eli Lilly and Company's (NYSE: LLY) SURPASS-3 and SURPASS-5 phase 3 clinical trials after 52 weeks and 40 weeks, respectively. In...

Tirzepatide significantly reduced A1C and body weight in people with type 2 diabetes in two phase 3 trials from Lilly's SURPASS program

INDIANAPOLIS, Feb. 17, 2021 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has elected Kimberly H. Johnson as a new member, effective February 16, 2021. As a member of Lilly's board, she will serve on both the Compensation Committee and the Ethics and...

Kimberly H. Johnson Elected to Lilly Board of Directors

Adagene

I-Mab

Morphosys AG - ADR

Adagene completed a $140 million NASDAQ IPO and climbed 56% higher in open market trading. Nuance Pharma in-licensed Greater China rights to a late-stage candidate for osteoarthritis pain from Antibe Therapeutics in a $100 million agreement.

Week In Review: Suzhou's Adagen Raises $140 Million In U.S. IPO To Develop Oncology Drugs

Eli Lilly and Co.'s (NYSE:LLY) 28% increase in share price in 2020 was the highest among members of big [harma. According to an Evaluate Pharma report, the gain pushed the company's market value to more than $161 billion.

Eli Lilly Keeps Piling Up Share Price Gains

INDIANAPOLIS, Feb. 11, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will participate in the 10th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 24, 2021. Ilya Yuffa, Lilly senior vice president and president of Lilly Bio-Medicines, will participate in a...

Lilly To Participate in SVB Leerink Global Healthcare Conference

GlaxoSmithKline

Moderna

Sorrento Therapeutics Inc

Vir Biotechnology

These biotech companies may be among the winners of the coronavirus treatment race -- if all goes well in clinical trials.

How Risky Are These Heavily Shorted COVID Stocks?

Shares of IPO stock AbCellera Biologics returned gains Wednesday after its Eli Lilly-partnered Covid-19 treatment nabbed a Food and Drug Administration second emergency use authorization. The post IPO Stock Returns Bullish Gains After Lilly-Partnered Covid Drug Nabs OK appeared first on Investor's Business Daily.

IPO Stock Returns Bullish Gains After Lilly-Partnered Covid Drug Nabs OK

FDA grants EUA to Eli Lilly's (LLY) COVID-19 antibody cocktail. FDA also authorizes shortened infusion time for bamlanivimab/etesevimab.

Lilly (LLY) COVID-19 Antibody Combo Gets FDA's Emergency Nod

Shares of Eli Lilly & Co. were up 1.1% in premarket trading on Wednesday, the day after the Food and Drug Administration granted emergency authorization to the company's COVID-19 antibody cocktail. The infusion pairs two monoclonal antibodies, bamlanivimab and etesevimab, as a treatment for anyone older than 12 years old who has mild to moderate COVID-19 symptoms and is at risk for severe disease.

FDA grants authorization to Lilly's COVID-19 antibody treatment

According to Wall Street Journal, Eli Lilly And Co's (NYSE: LLY) said it wouldn't try to claw back past pay from departed finance chief Joshua Smiley. Smiley's resignation wasn't related to financial controls, financial statements, or other business matters or judgments.

Eli Lilly Doesn't Plan To Claw Back Past Pay From Former CFO

Eli Lilly and Co (NYSE: LLY)'s antibody treatments have received an emergency use authorization from the United States Food and Drug Administration. What Happened: The federal regulator issued the EUA for the two drugs, bamlanivimab and etesevimab, to be administered together for the treatment of mild to moderate COVID-19 in both adults and children above 12 years of age.

Eli Lilly Antibody Drug Combo For COVID-19 Gets FDA Emergency Approval

INDIANAPOLIS, Feb. 9, 2021 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) for investigational bamlanivimab (LY-CoV555) 700 mg and etesevimab (LY-CoV016) 1400 mg together, Eli Lilly and Company (NYSE: LLY) announced today. This therapy...

Lilly's bamlanivimab (LY-CoV555) administered with etesevimab (LY-CoV016) receives FDA emergency use authorization for COVID-19

ABBV vs. LLY: Which Stock Is the Better Value Option?

ABBV or LLY: Which Is the Better Value Stock Right Now?

Eli Lilly's chief financial officer resigned Tuesday following a misconduct investigation. The pharmaceutical giant said CFO Josh Smiley will step down after an independent counsel revealed "consensual though inappropriate" personal messages between the executive and employees.

Eli Lilly's chief financial officer resigned after a misconduct investigation revealed he sent 'consensual though inappropriate' personal messages to employees (LLY)

Eli Lilly said Tuesday Chief Financial Officer Josh Smiley had resigned after allegations about a personal relationship sparked an investigation that found “inappropriate personal communication” with some Lilly employees. The drugmaker said it immediately hired external counsel to conduct an independent probe after it was made aware of the allegations.

Eli Lilly CFO Josh Smiley resigns after probe into ‘inappropriate' relationship

Eli Lilly And Co's (NYSE: LLY) Chief Financial Officer Josh Smiley resigned after an independent investigation found inappropriate personal communication with some Lilly employees.  The investigation revealed consensual though inappropriate personal communications between Smiley and certain Lilly employees.

Eli Lilly's CFO To Step Down Amid Inappropriate Employee Relationship Allegations

Eli Lilly and Co. (NYSE: LLY) is shuffling the executive deck on Tuesday after allegations about inappropriate communication arose against Chief Financial Officer Josh Smiley.

Eli Lilly Dumps CFO After Inappropriate Communication Allegations Arise

Eli Lilly announced that Josh Smiley, its chief financial officer and senior vice president, has resigned after an investigation revealed "inappropriate personal communications" with employees.

Eli Lilly CFO resigns after 'inappropriate' communications with employees

Eli Lilly and Co said on Tuesday its chief financial officer Josh Smiley will step down after an independent investigation found inappropriate personal communication with certain Lilly employees.

Eli Lilly says CFO to step down after 'inappropriate communication' with employees

Shares of Eli Lilly & Co. were down 0.3% in premarket trading on Tuesday after the drugmaker said chief financial officer Josh Smiley will resign after engaging in inappropriate personal communications with some employees. He had a personal relationship with an employee, which was found to be consensual.

Lilly promotes Anat Ashkenazi to CFO, says previous CFO had 'inappropriate' communication with employees

Coherus BioSciences

Dynavax Technologies

Exelixis

Illumina

Week In Review: Junshi Signs $1.1 Billion Deal For U.S.-Canada Rights To PD-1

Alibaba

Cisco Systems

Salesforce

State Teachers Retirement System of Ohio materially lifted investments in Alibaba, Eli Lilly, and Cisco Systems, and halved holdings in Salesforce.com in the fourth quarter.

Big Pension Buys Up Alibaba, Lilly, and Cisco Stock. Here's What It Sold.

INDIANAPOLIS, Feb. 4, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will conduct a webcast on Monday, March 15, 2021 to provide an update on its Alzheimer's disease program and discuss results from the Phase 2 TRAILBLAZER-ALZ study for donanemab being presented at the 15th...

Lilly Announces Webcast to Provide Alzheimer's Disease Update at AD/PD Conference

INDIANAPOLIS, Feb. 3, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in the Guggenheim Healthcare Talks 2021 Oncology Day on Friday, February 12, 2021. Anne White, senior vice president and president, Lilly Oncology, and Jacob Van Naarden, chief executive officer...

Lilly to Participate in Guggenheim Healthcare Talks 2021 Oncology Day

Eli Lilly and Company (NYSE: LLY) and its collaborating partner Innovent Biologics Inc IVBXF has announced that the National Medical Products Administration (NMPA) of China has approved the supplemental marketing application seeking approval for TYVYT (sintilimab injection) in combination with pemetrexed and platinum chemotherapy as first-line therapy for people with nonsquamous non-small cell lung cancer.

News for Eli Lilly Stock (LLY)